(Q34401527)

English

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

Robert J Moots

1

1 reference

Europe PubMed Central

1 August 2017

Barbara Naisbett-Groet

2

1 reference

Europe PubMed Central

1 August 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

51

1 reference

Europe PubMed Central

1 August 2017

12

1 reference

Europe PubMed Central

1 August 2017

2252-2261

1 reference

Europe PubMed Central

1 August 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Switching tumor necrosis factor inhibitors: an opinion

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES217

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KES217

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34401527&oldid=1595259699"